Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Martijn W C VerbeekChiara BuracchiAnna LaquaStefan NierkensLukasz SedekJuan Flores-MonteroMattias HofmansElaine Sobral de CostaMichaela NovákováEster MejstrikovaSusana BarrenaSaskia KohlscheenMonika SzczepanowskiJan KulisElen OliveiraRomana JugooaAnja X de JongShaji K KumarJan PhilippéJacques J M van DongenAlberto OrfaoMonika BrüggemannGiuseppe GaipaVincent H J van der VeldenPublished in: British journal of haematology (2021)
The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
Keyphrases
- liver failure
- nk cells
- end stage renal disease
- randomized controlled trial
- newly diagnosed
- ejection fraction
- drug induced
- chronic kidney disease
- respiratory failure
- radiation therapy
- mass spectrometry
- intensive care unit
- drug delivery
- machine learning
- artificial intelligence
- rectal cancer
- molecularly imprinted
- patient reported
- fluorescent probe
- living cells